GENFIT Says Iqirvo Is First-ever Drug Developed In-house By Company To Achieve FDA Approval; Expects To Receive Milestone Payments From Ipsen
$GNFT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
GENFIT is eligible to receive a €48.7 million milestone payment from Ipsen upon the first commercial sale of Iqirvo in the U.S., as well as tiered double-digit royalties of up to 20%.
Ipsen's Iqirvo (elafibranor) 80 mg tablets received U.S. FDA accelerated approval as a first-in-class treatment for Primary Biliary Cholangitis (PBC).